Phosphodiesterase type 5 inhibitors (PDE5-Is) have been increasingly used in the medical treatment of benign prostatic hyperplasia (BPH) in recent years. Many urologists cautiously approached extending the indications of PDE5-Is, and it has found a place especially among the recommended treatments with an increasing number of reports with a high level of evidence.
Understanding the satisfactory results of PDE5-Is in the symptomatic resolution of the condition is based on the details of the mechanism of effect of the agent. This article is protected by copyright. All rights reserved.
Journal of clinical pharmacology. 2015 Aug 27 [Epub ahead of print]
Hakan Ozturk
Department of Urology, School of Medicine, Sifa University, Izmir, Turkey.